Publisher
Springer International Publishing
Reference44 articles.
1. Rogosnitzky M, Branch S. Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. Biometals. 2016;29(3):365–76. https://doi.org/10.1007/s10534-016-9931-7.
2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019596s057lbl.pdf. Accessed 20 Apr 2021.
3. Seale MK, Catalano OA, Saini S, Hahn PF, Sahani DV. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics. 2009;29(6):1725–48. https://doi.org/10.1148/rg.296095515.
4. Rapp JH, Wolff SD, Quinn SF, Soto JA, Meranze SG, Muluk S, Blebea J, Johnson SP, Rofsky NM, Duerinckx A, Foster GS, Kent KC, Moneta G, Middlebrook MR, Narra VR, Toombs BD, Pollak J, Yucel EK, Shamsi K, Weisskoff RM. Aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease: safety and efficacy of gadofosveset-enhanced MR angiography—multicenter comparative phase III study. Radiology. 2005;236(1):71–8. https://doi.org/10.1148/radiol.2361040148.
5. https://www.radiologysolutions.bayer.com/sites/g/files/kmftyc641/files/PP-MAG-US-0017-1%20Magnevsit%20Withdrawal%20Customer%20Letter%20%28web%20page%29%20Promotional%20Labeling%2020190815%20Clean.pdf. Accessed 20 Apr 2021.